Obermatt
See Similar Stocks →

Flags

Financial distress

OSE Immunotherapeutics

PAR:OSE · FR0012127173
BiotechnologySmall

360

31
Profit price60
Owner Earnings Yield1
Dividend Yield1
Price/Sales71
EV / Gross Profit21
Price/Book44
Return on Capital62
Cash Return on Capital31
Return on Equity33
Profit margins39

Cash truth not applicable for financial companies.

Sales growth9
Profit growth66
Reinvestment68
Price momentum13
Debt load34
Refinancing23
Debt Payback1
Liquidity92
Analyst ratings100
Opinion Changes50
Price Target Upside80
Market mood45

Profile

CountryFrance
IndustryBiotechnology
SizeSmall
TypePublic Company
ExchangeENXTPA
Founded2016
Employees80
Websiteose-immuno.com
ISINFR0012127173
Last UpdateApr 2, 2026
Indices
CAC All (France)
Themes
RheumatologyImmunologyOncologyInflammationBiotechnologyMedicalMedical DevicePharmaceutical

Description

Analysis

Hope premium

OSE Immunotherapeutics SA is priced well ahead of what the underlying numbers justify, a pattern we describe as a hope premium.

Valuation data is not available for this company.

Growth is moderate; the safety picture is stretched.

No flags apply to this company at this time: accounts, balance sheet, and cash quality all pass. A clean bill of health is meaningful, not just the absence of a warning. This analysis describes numbers; it is not investment advice.

Detailed & Historical Ranks

Deep dive into 15 detailed ranks and 3 years of history.

Current202520242023
Price/Sales
71
—
—
—
Price/Earnings
61
—
—
—
Price/Book
44
—
—
—
Dividend Yield
1
—
—
—
Value (overall)
67
—
—
—

Cells are coloured by rank band (red weak → green strong). Sentiment & 360° history begins 2023.

Similar Stocks

The companies this stock is ranked against.

Compare OSE Immunotherapeutics with its peers
Innate Pharma
PAR:IPH
54
CountryFrance
IndustryBiotechnology
SizeSmall
Full Stock Analysis →
NewAmsterdam Pharma Company
NMQ:NAMS
16
CountryNetherlands
IndustryBiotechnology
SizeSmall
Full Stock Analysis →
Compugen
NAQ:CGEN
19
CountryIsrael
IndustryBiotechnology
SizeSmall
Full Stock Analysis →
OKYO Pharma
NAQ:OKYO
40
CountryUK
IndustryBiotechnology
SizeX-Small
Full Stock Analysis →
BioNTech
NSQ:BNTX
11
CountryGermany
IndustryBiotechnology
SizeLarge
Full Stock Analysis →
Centessa Pharmaceuticals
NSQ:CNTA
28
CountryUK
IndustryBiotechnology
SizeSmall
Full Stock Analysis →

Make Sense of the Ranks

Every rank runs 1–100 against true peers. Higher is always better.

360° View
1 · Watch OutGood· 100
Value
1 · ExpensiveGood Value· 100
Quality
1 · Weak FundamentalsHigh Quality· 100
Growth
1 · Tough TimesHigh Growth· 100
Safety
1 · High LeverageWell-Financed· 100
Sentiment
1 · SkepticismPositive· 100
Learn More →